PROLIA (also known as Denosumab)
Mechanism:
Prolia is an antibody that inhibits RANK-Ligand, which leads to the protection of bone mass from degradation.
Indications:
Contraindications:
Patients with hypocalcemia, especially with concurrent renal impairment, should consult their physicians and have their calcium levels corrected before initiating Prolia.
Administration:
Prolia is typically administered as a subcutaneous injection by a healthcare professional every 6 months.